Danish state bankruptcy of 1813

Gas Storage Denmark and Fidelis New Energy enter into a Collaboration on CO2 Storage

Retrieved on: 
Monday, May 15, 2023
Carbon, Partnership, Collaboration, GSD, Danish state bankruptcy of 1813, Fidelis, Knowledge, Entrepreneurship, CO2, Renewable energy, EU, Danish

COPENHAGEN, Denmark, May 15, 2023 /PRNewswire/ -- Gas Storage Denmark ("GSD") and Fidelis New Energy ("Fidelis") are proud to announce they have entered into collaboration concerning Fidelis' development, delivery, and operations of the Norne Carbon Storage Hub, a large, safe, and cost-effective onshore carbon storage system in Denmark.

Key Points: 
  • COPENHAGEN, Denmark, May 15, 2023 /PRNewswire/ -- Gas Storage Denmark ("GSD") and Fidelis New Energy ("Fidelis") are proud to announce they have entered into collaboration concerning Fidelis' development, delivery, and operations of the Norne Carbon Storage Hub, a large, safe, and cost-effective onshore carbon storage system in Denmark.
  • Fidelis is developing the Norne Carbon Storage Hub, an onshore CO2 storage network in Denmark using the country's attractive subsurface characteristics for national and international CO2 storage.
  • "We are thrilled to announce our collaboration with Gas Storage Denmark, for their knowledge and experience will assist us in supporting the development of the Norne Carbon Storage Hub," says Ulrik Weuder of Fidelis New Energy Europe.
  • Gas Storage Denmark joins this important collaboration, as an knowledge and competence partner to develop the Norne Carbon Storage Hub with Fidelis and Ross Energy ( see press release here ) the partnership's well management and subsurface development partner.

Alphalyse and Bavarian Nordic A/S significantly shorten the time necessary to document HCP impurities in COVID-19 vaccine candidate for Phase 3 clinical trial – through world’s first MS-based HCP analysis under GMP conditions

Retrieved on: 
Tuesday, January 3, 2023
Danish state bankruptcy of 1813, Host cell protein, GMP, VLP, MS, API, COVID-19, HCPS, LC-MS, HCP, Severe acute respiratory syndrome coronavirus 2, DKK, Safety, Bavarian Nordic, ELISA, Mass spectrometry, Vaccine, Documentation, Danish Health Authority, Health

On September 2, 2022, Bavarian Nordic A/S announced the start of Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.

Key Points: 
  • On September 2, 2022, Bavarian Nordic A/S announced the start of Phase 3 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 booster vaccine candidate.
  • The goal is to create a longer-lasting vaccine protection with broader efficacy that obviates the need for continuously adapting to new variants of the SARS-CoV-2 virus.
  • Prior to the Phase 3 clinical trial, Bavarian Nordic contracted Alphalyse to perform product release testing under GMP conditions, thereby becoming the first pharmaceutical company in the world to use MS-based HCP analysis for Phase 3 clinical trial documentation.
  • This makes the Alphalyse method particularly useful for developing vaccines during a global pandemic when the time to create a process-specific ELISA is limited.

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate

Retrieved on: 
Thursday, May 5, 2022
OMX, COVID-19, Respiratory syncytial virus, Forward-looking statement, Immune system, Omicron, RSV, Rabies, Government, Janssen Pharmaceuticals, Johnson & Johnson, Danish state bankruptcy of 1813, Program, FDA, Monkeypox, VLP, Alpha, Licensure, Vaccine, Tick-borne encephalitis, Vaccination, Goal, Smallpox vaccine, RNA transfection, Technology, CEO, Nasdaq Copenhagen, ExpreS2ion Biotechnologies, Bavarian Nordic

COPENHAGEN, Denmark, May 5, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today additional results from its Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 vaccine candidate.

Key Points: 
  • COPENHAGEN, Denmark, May 5, 2022 Bavarian Nordic A/S (OMX: BAVA) announced today additional results from its Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 vaccine candidate.
  • Paul Chaplin, President and CEO of Bavarian Nordic, commented: We now have demonstrated a large range of immune responses against different variants of concern, including Omicron.
  • Supported by the Danish State, Bavarian Nordic plans to initiate soon a Phase 3 program of ABNCoV2.
  • Bavarian Nordic has licensed the global commercialization rights to the vaccine and has assumed the responsibility for further clinical development towards licensure.

Notice of the 2022 annual general meeting of Ørsted A/S

Retrieved on: 
Wednesday, March 16, 2022
Danish state bankruptcy of 1813, Ministry, Board of directors, RTÉ Executive Board, Ministry of Finance (Netherlands), A/S, Capital market, Board, Danish, C25, Policy, Remuneration, Management, Holding company, Director

The annual general meeting of rsted A/S will be held on Friday, 8 April 2022, at 10:00 CEST.

Key Points: 
  • The annual general meeting of rsted A/S will be held on Friday, 8 April 2022, at 10:00 CEST.
  • The meeting will be held at Villa Copenhagen, Tietgensgade 35-39, 1704, Copenhagen K, Denmark.
  • The agenda for the annual general meeting is:
    Proposals from the Board of Directors:
    A decision to amend the Remuneration Policy for the Board of Directors and the Executive Board.
  • The agenda is further described in the enclosed notice of the annual general meeting.